

PATRICK H. NACHMAN, MD

CURRICULUM VITAE

UNC Kidney Center
7004 Burnett Womack Building
CB #7155
University of North Carolina
Chapel Hill, NC 27599

Phone: 919.445.2685
Fax: 919.966.4251
patrick_nachman@med.unc.edu

EDUCATION

Fellowship in Nephrology:	University of North Carolina at Chapel Hill: 7/1995 - 6/1996
Research Fellowship in Nephrology:	University of North Carolina at Chapel Hill: 7/1992 - 7/1995
Residency in Internal Medicine:	University of North Carolina at Chapel Hill: 7/1990 - 6/1992
Internal Medicine Internship:	University of North Carolina at Chapel Hill: 7/1989 - 6/1990
Medical School:	Boston University School of Medicine, Boston, Massachusetts, Doctor of Medicine: 5/1989 American University of Beirut, Beirut, Lebanon: 9/1983 - 1/1985
College:	American University of Beirut, Beirut, Lebanon B.S. in Biology, Graduated with Distinction: 6/1983

EMPLOYMENT HISTORY

Deputy Director, UNC Kidney Center: University of North Carolina, 12/2015-present
Professor of Medicine: University of North Carolina at Chapel Hill, 8/2009 - present
Associate Professor of Medicine: University of North Carolina at Chapel Hill, 4/2003 - 7/2009
Assistant Professor of Medicine: University of North Carolina at Chapel Hill, 7/1996 - 3/2003

Board Certification

American Board of Medicine: Nephrology and Hypertension Number 146290. September 1996, 2006
American Board of Internal Medicine: September 1992
National Boards: Certificate Number 381338, July 1990

Honors and Awards

- ♦ 2015 UNC Health Care and Faculty Physicians Award for Carolina Care Excellence
- ♦ Best Doctors in America, 2008 - present
- ♦ Internal Medicine Housestaff Faculty Award, May 2007
- ♦ Dr. Samuel Poplack Student Award for superior clinical competence and excellence in patient care. Boston University School of Medicine, May 1989
- ♦ B.S. degree with Distinction, American University of Beirut, June 1983

BIBLIOGRAPHY

Contributions in Textbooks

1. McGregor JA, Nachman PH and Falk RJ. Vasculitic Diseases of the Kidney. In: Schrier's Diseases Of The Kidney. 9th edition. Lippincott Williams & Wilkins, Philadelphia, PA 2012.
2. Nachman PH, Jennette, JC and Falk RJ. Chapter 31: Primary Glomerular Disease. In: Brenner's The Kidney. 9th edition W.B. Saunders Company, Philadelphia, PA. 2012.
3. Derebail, V and Nachman PH. In: Chapter 38: Vasculitides. In: Nephrology Secrets, 3rd Edition. Mosby. Edited by Edgar V. Lerma and Allen R. Nissenson, 2011. p. 271-277.
4. Nachman PH, Glasscock RJ. Crescentic glomerulonephritis. In: Treatment of Primary Glomerulonephritis. Edited by Ponticelli C and Glasscock RJ. Second edition. Oxford Clinical Nephrology Series. Oxford University Press. 2009: p. 399-435.
5. Nachman PH, Denu-Ciocca C. Vasculitides. In: Current Diagnosis and Treatment in Nephrology and Hypertension. Edited by Edgar V. Lerma, Allen R. Nissenson and Jeffrey S. Berns. Lange CURRENT series. McGraw-Hill 2009: p. 265-275.
6. Nachman PH and Falk RJ: Glomerulonephritis. In: Netter's Internal Medicine. Edited by Runge MS and Greganti MA. 2nd Edition. Icon Learning Systems. 2009: p. 991-998.
7. Nachman PH: Nephrotic Syndrome. In: Netter's Internal Medicine. Edited by Runge MS and Greganti MA. 2nd Edition. Icon Learning Systems. 2009: p. 999-1008.
8. Sanoff, S and Nachman PH: Hematuria. In: Netter's Internal Medicine. Edited by Runge MS and Greganti MA. 2nd Edition. Icon Learning Systems. 2009: p. 962-967.
9. Nachman PH, Jennette, JC and Falk RJ. Primary Glomerular Disease. In: Brenner's The Kidney. 8th edition W.B. Saunders Company, Philadelphia, PA. 2008: p. 987-1066.
10. Nachman PH, Jennette, JC and Falk RJ. Vasculitic Diseases of the Kidney. In: Schrier's Diseases of the Kidney. 8th edition Lippincott Williams & Wilkins, Philadelphia, PA. 2007 Chapter 68: 1748-1775.
11. Nachman PH and Dooley MA. Systemic Lupus Erythematosus. In: Primer on Kidney Diseases 4th edition Edited by Arthur Greenberg 2005 Chapter 27, p. 234-240.
12. Falk RJ, Jennette, JC and Nachman PH. Primary Glomerular Disease. In: Brenner's The Kidney. 7th edition W.B. Saunders Company, Philadelphia, PA. Chapter 28, p. 1293-1380.
13. Nachman PH and Falk RJ: Glomerulonephritis. In: Netter's Internal Medicine. Edited by Runge MS and Greganti MA. Icon Learning Systems. 2003: Chapter 114, p. 755-763.
14. Nachman PH: Nephrotic Syndrome. In: Netter's Internal Medicine. Edited by Runge MS and Greganti MA. Icon Learning Systems. 2003: p. 771-778.
15. Nachman PH: Acute Renal Failure In Vasculitis. In: Acute Renal Failure. Edited by Molitoris and Finn. W.B. Saunders Company, Philadelphia, PA. 2001: Chapter 21, p. 275-291.
16. Nachman PH, Jennette, JC and Falk RJ. Vasculitic Diseases of the Kidney. In Schrier's Diseases of the Kidney. 7th edition Lippincott Williams & Wilkins, Philadelphia, PA. 2000; Chapter 68. 1911-1938.
17. Nachman PH and Falk RJ: Treatment of ANCA-Associated Small Vessel Vasculitis. In: Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's The Kidney; edited by Brady HR and Wilcox. W.B. Saunders Company, Philadelphia, PA. 1999: Chapter 23: 158-164.
18. Nachman PH, Falk RJ and Jennette, JC: The Kidney in Systemic Disease. In: Clinical Nephrology, Dialysis and Transplantation. Edited by Malluch H.H., Sawaya B.P., Hakim R.M. and Sayegh M.H., Dusterl-Verglag, Dr Karl Feistle, Deisenhofen, Germany. 1999: Chapter I.8 p. 1-42.

19. Falk RJ, Jennette JC and Nachman PH. Primary Glomerular Disease. In: Brenner's The Kidney. 6th edition W.B. Saunders Company, Philadelphia, PA. 1996: Chapter 29, p. 1263-1349.
20. Nachman PH and Falk RJ: ANCA-Associated Small Vessel Vasculitis. In: Current Therapy in Nephrology and Hypertension, 4th edition. Edited by Glassock RJ. Mosby-Year Book, Philadelphia, PA. 1998: p. 161-165.
21. Nachman PH, Jennette JC, Falk RJ: Pathogenesis of Systemic Vasculitis. In: Rapidly Progressive Glomerulonephritis, edited by Rees AJ and Pusey CD, Oxford University Press, Oxford, London. 1998: Chapter 6:125-147.

Refereed Publications

Original Research

1. Lee T, Derebail VK, Kshirsagar AV, Chung Y, Fine JP, Mahoney S, Poulton CJ, Lionaki S, Hogan SL, Falk RJ, Cattran DC, Hladunewich M, Reich HN, Nachman PH. Patients with Primary Membranous Nephropathy Are at High-risk of Cardiovascular Events. *Kidney Int Feb 2016. Epub ahead of print*
2. Laurin LP, Gasim AM, Poulton CJ, Hogan SL, Jennette JC, Falk RJ, Foster BJ, Nachman PH. The role of early treatment with glucocorticoids or calcineurin inhibitors in primary focal segmental glomerulosclerosis. *Clin J Am Soc Nephrol. 2016. Feb Epub ahead of print.*
3. Gipson DS, Troost JP, Lafayette RA, Hladunewich MA, Trachtman H, Gadegebeku CA, Sedor JR, Holzman LB, Moxey-Mims MM, Perumal K, Kaskel FJ, Nelson PJ, Tuttle KR, Bagnasco SM, Hogan MC, Dell KM, Appel GB, Lieske JC, Ilori TO, Sethna CB, Fervenza FC, Hogan SL, Nachman PH, Rosenberg AZ, Greenbaum LA, Meyers KE, Hewitt SM, Choi MJ, Kopp JB, Zhdanova O, Hodgins JB, Johnstone DB, Adler SG, Avila-asado C, Neu AM, Hingorani SR, Lemley KV, Nast CC, Brady TM, Barisoni-Thomas L, Fornoni A, Jennette JC, Cattran DC, Palmer MB, Gibson KL, Reich HN, Mokrzycki MH, Sambandam KK, Zilleruelo GE, Licht C, Sampson MG, Song P, Mariani LH, Kretzler M. Complete Remission in the Nephrotic Syndrome Study Network. *Clin J Am Soc Nephrol. 2016 Jan 7;11(1):81-9.*
4. Thompson A, Cattran DC, Blank M, Nachman PH. Surrogate Endpoints in Primary Membranous Nephropathy: a Critical Evaluation of Complete and Partial Remission. *J Am Soc Nephrol 2015;26:2930-7*
5. Bunch DO, Mendoza CE, Aybar LT, Kotzen ES, Colby KR, Hu Y, Hogan SL, Poulton CJ, Schmitz JL, Falk RJ, Nachman PH, Pendergraft WF, McGregor JAG. Gleaning relapse risk from B cell phenotype: decreased CD5⁺ B cells portend a shorter time to relapse after B cell depletion in patients with ANCA-associated vasculitis. *Ann Rheum Dis 2015 ;74(9):1784-6.*
6. McGregor JAG, Negrete-Lopez R, Poulton CJ, Kidd JM, Katsanos SL, Goetz L, Hu Y, Nachman PH, Falk RJ, Hogan SL. Adverse Events and Infectious Burden, Microbes and Temporal Outline from Immunosuppressive Therapy in Antineutrophil Cytoplasmic Antibody Associated Vasculitis with Native Renal Function. *Nephrol Dial Transplant 2015, Suppl 1:i171-i181.*
7. McGregor JAG, Hogan SL, Kotzen ES, Poulton CJ, Hu Y, Negrete-Lopez, R, Kidd JM, Katsanos SL, Bunch DO, Nachman PH, Falk RJ. Rituximab as an Immunosuppressant in Anti-Neutrophil Cytoplasmic Antibody Associated Vasculitis. *Nephrol Dial Transplant 2015, Suppl 1:i123-i131.*
8. Nachman PH and Glassock R. Co-Editor. Glomerular, Vascular, and Interstitial Diseases of the Kidney. Nephrology Self-Assessment Program. (NephSAP). *J Am Soc Nephrol. NephSAP, 2014 online publication.*
9. Lee T, Gasim A, Derebail VK, Yunro C, McGregor JA, Lionaki S, Poulton CJ, Hogan SL, Jennette JC, Falk RJ and Nachman PH. Predictors of treatment outcomes in ANCA-associated vasculitis with severe kidney failure. *Clin J Am Soc Nephrol. 2014;9:905-13.*
10. Lee T, Biddle AK, Lionaki S, Derebail VK, Barbour S, Tannous S, Hladunewich MA, Hu Y, Poulton CJ, Mahoney S, Jennette JC, Hogan SL, Falk RJ, Cattran DC, Reich HN, and Nachman PH. Prophylactic anticoagulation in patients with membranous nephropathy: A Decision Analysis. *Kidney Int. 2014;85: 1412-20. <http://www.gntools.com>.*

11. Clark W, Derebail VK and Nachman PH. Co editor, Nephrology Self Assessment Program: Vaso-occlusive Diseases of the Kidney. J Am Soc Nephrol. NephSAP, 2014 online publication.
12. Laurin LP, Nachman PH, Desai PC, Ataga KI, Derebail VK. Hydroxyurea is associated with lower prevalence of albuminuria in adults with sickle cell disease. Nephrol Dialysis Transplant. 2014;29: 1211-8.
13. Roth AJ, Ooi JD, Hess JJ, van Timmeren MM, Berg EA, Poulton CE, McGregor J, Burkart M, Hogan SL, Hu Y, Winnik W, Nachman PH, Stegeman CA, Niles J, Heeringa P, Kitching AR, Holdsworth S, Jennette JC, Preston GA, Falk RJ. Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest. 2013;123(4):1773-83.
14. Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, Poulton CJ, Berg EA, Falk RJ, Nachman PH. Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol. 2013 Mar;8(3):382-91.
15. Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PX, Barisoni L, Sampson MG, Kopp JB, Lemley KV, Nelson PJ, Lienczewski CC, Adler SG, Appel GB, Cattran DC, Choi MJ, Contreras G, Dell KM, Fervenza FC, Gibson KL, Greenbaum LA, Hernandez JD, Hewitt SM, Hingorani SR, Hladunewich M, Hogan MC, Hogan SL, Kaskel FJ, Lieske JC, Meyers KE, Nachman PH, Nast CC, Neu AM, Reich HN, Sedor JR, Sethna CB, Trachtman H, Tuttle KR, Zhdanova O, Zilleruelo GE, Kretzler M. Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int. 2013;83(4):749-56.
16. Poulton CJ, Nachman PH, Hu Y, McGregor JG, Jennette JC, Falk RJ, Hogan SL. Pathways to renal biopsy and diagnosis among patients with ANCA small-vessel vasculitis. Clin Exp Rheumatol. 2013; 31(1 Suppl 75):S32-7.
17. Bunch DO, McGregor JG, Khandoobhai NB, Aybar LT, Burkart ME, Hu Y, Hogan SL, Poulton CJ, Berg EA, Falk RJ, Nachman PH. Decreased CD5+ B Cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol. 2013; 8(3):382-91.
18. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012; 367(25):2407-18.
19. Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, Nachman PH, Jennette JC, Falk RJ. Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012 Oct;64(10):3452-62.
20. Irazabal MV, Eirin A, Lieske J, Beck LH, Sethi S, Borland TM, Dillon JJ, Nachman PH, Nasr SH, Cornell LD, Leung N, Cattran DC, Fervenza FC. Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. Nephrol Dial). Transplant. 2013 Jan;28(1):137-46.
21. Nachman PH and Glassock R. Co-Editor. Glomerular, Vascular, and Interstitial Diseases of the Kidney. Nephrology Self-Assessment Program (NephSAP). 2012;11:140-217.
22. McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol. 2012 Feb;7(2):240-7.
23. Lionaki S, Derebail V, Hogan SL, Barbour S, Hladunewich M, Greenwald A, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH*, Reich HN*. Venous Thromboembolism in Patients with Membranous Nephropathy. Clin J Am Soc Nephrol. 2012;7(1):43-51. *contributed equally
24. Barbour SJ, Greenwald A, Djurdjev O, Levin A, Hladunewich MA, Nachman PH, Hogan SL, Cattran DC, Reich HN. Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Kidney Int. 2012;Jan;81(2):190-5.
25. Derebail VK, Nachman PH, Key NS, Ansede H, Falk RJ, Rosamond WD, Kshirsagar AV. Variant hemoglobin phenotypes may account for differential erythropoiesis-stimulating agent dosing in African-American hemodialysis patients. Kidney Int. 2011;80(9):992-999.

26. Hicks PJ, Langefeld CD, Lu L, Bleyer AJ, Divers J, Nachman PH, Derebail VK, Bowden DW, Freedman BI. Sick cell trait is not independently associated with susceptibility to end-stage renal disease in African Americans. *Kidney Int.* 2011;80(12):1339-1343.
27. Geetha D, Eirin A, True K, Valentina Irazabal M, Specks U, Seo P, Nachman P, Fervenza FC. Renal transplantation in antineutrophil cytoplasmic antibody-associated vasculitis: a multicenter experience. *Transplantation.* 2011 Jun 27;91:1370-1375.
28. Ataga KI, Brittain JE, Moore D, Jones SK, Hulkower B, Strayhorn D, Adam S, Redding-Lallinger R, Nachman P, Orringer EP. Urinary albumin excretion is associated with pulmonary hypertension in sickle cell disease: potential role of soluble fms-like tyrosine kinase-1. *Eur J Haematol.* 2010 Sep;85(3):257-63.
29. F.C. Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC. Rituximab Therapy in Idiopathic Membranous Nephropathy: A 2-year study. *Clin J Am Soc Nephrol.* 2010;5:2188-98.
30. Nachman PH and Glassock R. Co-Editor. Glomerular, Vascular, and Interstitial Diseases of the Kidney. Nephrology Self-Assessment Program.(NephSAP). 2010;9:123-200.
31. Derebail VK, Nachman PH, Key NS, Ansele H, Falk RJ, Kshirsagar AV. High prevalence of sickle cell trait in African Americans with ESRD. *J Am Soc Nephrol.* 2010;21:413-7.
32. Lionaki S, Hogan SL, Jennette CE, Hu Y, Hamra JB, Jennette JC, Falk RJ, Nachman PH. The clinical course of ANCA small-vessel vasculitis on chronic dialysis. *Kidney Int* 2009;76(6):644-51.
33. Bomback AS, Derebail VK, McGregor JG, Kshirsagar AV, Falk RJ, Nachman PH. Rituximab therapy for membranous nephropathy: a systematic review. *Clin J Am Soc Nephrol.* 2009 Apr;4(4):734-44.
34. Bunch DO, Silver JS, Majure MC Sullivan P, Alcorta DA, Chin H, Hogan SL, Lindstrom YI, Clarke SH, Falk RJ, Nachman PH. Maintenance of Tolerance by Regulation of Anti-myeloperoxidase B Cells. *J Am Soc Nephrol.* 2008;19(9):1763-73.
35. Pagnoux C, Chin H, Hogan SL, Falk RJ, Guillevin l, Nachman PH. Predictors of Treatment Resistance and Relapse in ANCA Small Vessel Vasculitis: Comparison of Two Independent Cohorts. *Arthritis Rheum.* 2008;58(9):2908-18.
36. Nachman PH and Glassock R. Co-Editor. Glomerular, Vascular, and Interstitial Diseases of the Kidney. Nephrology Self-Assessment Program (NephSAP). 2008;7,131-207.
37. Lionaki S, Hogan SL, Falk RJ, Joy MS, Chin H, Jennette CE, Jennette JC, Nachman PH. Association of thyroid disease and its treatment with ANCA small vessel vasculitis: A case-control study. *Nephrol Dial Transplant.* 2007;22:3508-15.
38. Culton DA, Nicholas MW, Bunch DO, Zhen QL, Kepler TB, Dooley MA, Mohan C, Nachman PH, Clarke SH. Similar CD19 dysregulation in two autoantibody-associated autoimmune diseases suggests a shared mechanism of B cell tolerance loss. *J Clin Immunol* 2007. Jan;27(1):53-68.
39. Erdbrugger U, Hellmark T, Bunch DO, Alcorta DA, Jennette JC, Falk RJ, Nachman PH. Mapping of myeloperoxidase epitopes recognized by MPO-ANCA using human-mouse MPO chimeras. *Kidney Int.* 2006 May;69(10):1799-805.
40. Joy MS, Hogan SL, Jennette JC, Falk RJ, Nachman PH. A pilot study using mycophenolate mofetil in relapsing or resistant ANCA small vessel vasculitis. *Nephrol Dial Transplant.* 2005 Dec;20(12):2725-32.
41. Hogan SL, Falk RJ, Chin H, Cai J, Jennette CE, Jennette JC, Nachman PH. Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. *Ann Intern Med.* 2005 Nov 1;143(9):621-31.
42. Yang JJ, Pendergraft WF, Alcorta DA, Nachman PH, Hogan SL, Thomas RP, Sullivan P, Jennette JC, Falk RJ, Preston GA. Circumvention of normal constraints on granule protein gene expression in peripheral blood neutrophils and monocytes of patients with antineutrophil cytoplasmic autoantibody-associated glomerulonephritis. *J Am Soc Nephrol.* 2004 Aug;15(8):2103-14.

43. Patry YC, Nachman PH, Audrain MA, Falk RJ, Meflah K, Esnault VL. Difference in antigenic determinant profiles between human and rat myeloperoxidase. *Clin Exp Immunol*. 2003 Jun;132(3):505-8.
44. Joy MS, Cefalu WT, Hogan SL, Nachman PH. Long-term glycemic control measurements in diabetic patients receiving hemodialysis. *Am J Kidney Dis*. 2002 Feb;39(2):297-307.
45. Hogan SL, Satterly KK, Dooley MA, Nachman PH, Jennette JC, Falk RF. Silica exposure in ANCA-associated glomerulonephritis and lupus nephritis. *J Am Soc Nephrol*. 2001 Jan;12(1):134-142.
46. Jethwa HS, Clarke SH, Itoh-Lindstrom Y, Falk RJ, Jennette JC, Nachman PH. Restriction In V Kappa gene use and antigen selection in anti-myeloperoxidase response in mice. *J Immunol*. 2000 Oct 1;165(7):3890-7.
47. Jethwa HS, Nachman PH, Falk RJ, Kinjoh K, Jennette JC. False Positive myeloperoxidase binding activity due to DNA/anti-DNA antibody complexes: a source for analytical error in serologic evaluation of antineutrophil cytoplasmic autoantibodies. *Clin Exp Immunol*. 2000 Sept;121(3):544-50.
48. Dooley MA, Cosio FG, Nachman PH, Falkenhain ME, Hogan SL, Falk RJ, Hebert LA. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. *J Am Soc Nephrol*. 1999;10:833-9.
49. Nachman PH, Segelmark M, Westman K, Hogan SL, Satterly KK, Jennette JC and Falk RJ. Recurrent ANCA-small vessel vasculitis after transplantation: a pooled analysis. *Kidney Int*. 1999;56:1544-50.
50. Nachman PH, Joy MS. Glycosylated hemoglobin in the care of patients with diabetes mellitus. *Anna Journal*. 1998;25(2):245-6.
51. Nachman PH, Hogan SL, Jennette JC, Falk RJ. Treatment response in patients with ANCA-associated microscopic polyangiitis and glomerulonephritis. *J Am Soc Nephrol*. 1996;6:33-39.
52. Hogan SL, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Prognostic markers in patients with ANCA-associated microscopic polyangiitis glomerulonephritis. *J Am Soc Nephrol*. 1996;6:23-32.
53. Nachman PH, Reisner HM, Yang JJ, Jennette JC, Falk RJ: Shared idiotypy among patients with myeloperoxidase-ANCA-associated glomerulonephritis and vasculitis. *Lab Invest*. 1996;74:519-27.


Other Peer-Reviewed Articles

1. Pendergraft WF, Nachman PH. Recent Pathogenetic Advances in ANCA Vasculitis. *Presse Medicale* 2015, 44(6 Pt 2):e223-9
2. Co-author. KDIGO Clinical Practice Guideline for Glomerulonephritis: *Kidney Int Supplement*. 2012;2(2)139-274.
3. Nachman PH, Henderson AG. Pathogenesis of lung vasculitis. *Semin Respir Crit Care Med*. 2011; 32:245-53.
4. Nachman PH. Vasculitis syndromes: which maintenance therapy for ANCA vasculitis? *Nat Rev Nephrol*. 2009 May;5(5):254-6.
5. Lionaki S, Hogan SL, Falk RJ, Joy MS, Jennette CE, Nachman PH, Jennette JC. Vasculitis and anti-thyroid medication. *Nephrol Dial Transplant*. 2008;23:1766-8.
6. Cattran DC, Alexopoulos E, Heering P, Hoyer PF, Johnston A, Meyrier A, Ponticelli C, Saito T, Choukroun G, Nachman P, Praga M, Yoshikawa N. Cyclosporin in idiopathic glomerular disease associated with the nephrotic syndrome (INS): workshop recommendations. *Kidney International*. 2007;72:1429-47.
7. Nachman PH, Boffa J-J, Falk RJ. Traitement des formes résistantes et récidivantes des vascularites à ANCA. *Actualités Néphrologiques Jean Hamburger. Hôpital Necker*. 2006 ;77-90.
8. Hogan SL, Falk RJ, Nachman PH, Jennette JC. Various forms of life in antineutrophil cytoplasmic antibody-associated vasculitis. *Ann Intern Med*. 2006;144(5):377-8; author reply 378-9.
9. Kshirsagar AV, Nachman PH, Falk RJ. Alternative therapies and future intervention for treatment of membranous nephropathy. *Semin Nephrol*. 2003 Jul;23(4):362-72.
10. Nachman PH, Martin J. Developments in the Immunotherapy of Glomerular Disease. *J Pharm Practice*. 2002;(15)472-489.

11. Falk RJ, Hogan SL, Nachman PH, Jennette JC. Prognosis and treatment of systemic vasculitis: what is new? Clin Exp Immunol. 2000;120(Suppl 1):11-12.
12. Falk RJ, Nachman PH, Jennette JC. Immunopathogenesis of small vessel vasculitis. Clin Exp Immunol. 2000;120(Suppl 1):21-22.
13. Falk RJ, Nachman PH, Hogan SL, Jennette JC. ANCA Glomerulonephritis and vasculitis: a Chapel Hill perspective. Sem Nephrol. 2000;20:233-43.

Appears this way on the original

Published Abstracts

1. Laurin LP, Foster BJ, Gasim A, Poulton CJ, Jennette JC, Falk RJ, Nachman PH. The Role of Calcineurin Inhibitors in Early Treatment of Primary FSGS. *J Am Soc Nephrol* 26: 2015
2. Lee T, Derebail VK, Cattran DC, Falk RJ, Reich HN, Nachman PH. In Primary Membranous Nephropathy, Relapse After Partial Remission Is Predicted by Serum Albumin Level. *J Am Soc Nephrol* 26: 2015
3. Lee T, Derebail VK, Cattran DC, Falk RJ, Reich HN, Nachman PH. Clinical Significance and Risk Factor of Relapse in Proteinuria in Primary Membranous Nephropathy. *J Am Soc Nephrol* 26: 2015
4. Katsanos SL, Nachman PH, McGregor JAG, Nickenleit V. Collapsing and NOS Focal Segmental Glomerulosclerosis (FSGS): Progression Along a Spectrum or Different Diseases? *J Am Soc Nephrol* 26: 2015
5. Swain KA, Liu H, Nickenleit V, Nachman PH. A Curious SLE Tangled Case: Systemic Lupus Erythematosus as the Unifying Diagnosis for Fibrillary Glomerulopathy and Toxic Epidermal Necrolysis. *J Am Soc Nephrol* 26: 2015
6. Brant EJ, Mendoza CE, Hu Y, Hogan SL, Falk RJ, Nachman PH, Derebail VK, Bunch DO. Venous Thromboembolism in ANCA Vasculitis Is Associated with Elevated Microparticle Tissue Factor Activity. *J Am Soc Nephrol* 26: 2015
7.  (b) (4)
8. *J Am Soc Nephrol* 26: 2015 Laurin LP, Foster BJ, Gasim A, Poulton CJ, Jennette JC, Falk RJ, Nachman PH. Factors Influencing Initiation and Choice of Immunosuppressive Therapy in Primary FSGS. *J Am Soc Nephrol* 26: 2015
9. Lee T, Derebail VK, Kshirsagar AV, Poulton CJ, Hogan SL, Lionaki S, Falk RJ, Reich HN, Nachman PH. The Risk of Cardiovascular events (CVE) is Greater in Membranous Nephropathy (MN) Than Focal Segmental Glomerulosclerosis (FSGS). *J Am Soc Nephrol* 25: 2014
10. Brown LC, Free ME, Chang EH, Laurin LP, Falk RJ, Nachman PH, Pendergraft WF. Rituximab-Induced B Cell Depletion for Treatment of Refractory Minimal Change Glomerulopathy. *J Am Soc Nephrol* 25: 2014.
11. Troost J, Selewski DT, Nachman PH, Massengill SF, Herreshoff EG, Lienczewski CC, Klim AM, Gipson DS. Patient Reported Outcomes in Children and Adults with Nephrotic Syndrome. *J Am Soc Nephrol* 25: 2014.
12. Basta B, Nachman PH, Singh HK, Pendergraft WF, Hladik GA, Payan Schober F, Grossman SH. IgA Nephropathy (IgAN) and Pregnancy: The Challenge of Distinguishing between Preeclampsia and Progressive Glomerulonephritis (GN). *J Am Soc Nephrol* 25: 2014
13. McGregor JAG, Poulton CJ, Kidd JM, Katsanos SL, Goetz LR, Hu Y, Nachman PH, Falk RJ, Hogan SL. Timing and Types of Infections After Diagnosis and Antineutrophil Cytoplasmic Antibody Associated Vasculitis. *J Am Soc Nephrol* 25: 2014
14. Jain K, Gupta A, Swain KA, Nachman PH, True KA. Recurrent Immunotactoid Glomerulopathy in a Transplanted Kidney. *J Am Soc Nephrol* 25: 2014
15. Roth A, Ooi J, Hess J, Van Timmeren M, Berg E, Poulton C, McGregor J, Burkart M, Hogan S, Hu Y, Winnik W, Nachman P, Stegeman C, Niles J, Heeringa P, Free M, Kitching R, Holdsworth S, Jennette C, Preston G, Falk R. ANCA epitope specificity determines pathogenicity, detectability and clinical predictive value. *Presse Med.* 2013;42:664.
16. Lee T, Gasim A, McGregor JAG, Derebail VK, Poulton CJ, Lionaki S, Hogan SL, Jennette JC, Falk RJ, Nachman PH. Prognosis of patients with ANCA-associated glomerulonephritis (GN) presenting with severe renal failure. *Presse Med.* 2013;42:671.

17. Bunch D, McGregor JAG, Aybar L, Studhill E, Hu Y, Hogan S, Colby K, Poulton C, Mendoza C, Schmitz J, Falk R, Nachman P. Low %CD5 B cells in patients with ANCA vasculitis portends a shorter time to relapse after rituximab. *Presse Med.* 2013;42;754.
18. McGregor J, Negrete-Lopez R, Poulton C, Kidd J, Weaver S, Goetz L, Hu Y, Nachman P, Falk R, Hogan S. Infectious complications related to treatment in an inception cohort of antineutrophil cytoplasmic antibody-associated vasculitis. *Presse Med.* 2013;42;767.
19. Studhill ME, McGregor J, Poulton C, Hu Y, Nachman P, Falk R, Hogan S. Time to remission and relapse following rituximab in an inception cohort of antineutrophil cytoplasmic vasculitis. *Presse Med.* 2013;42;774.
20. Froment AB, Newton VM, Hogan SL, Hu Y, Belger A, Nachman PH, [FR-PO268] Detailed analysis of cognitive function in patients on hemodialysis (HD). *J Am Soc Nephrol.* 2012, 23.
21. Froment AB, Newton VM, Hogan SL, Hu Y, Belger A, Nachman PH, [FR-PO269] Longitudinal study of change in cognitive function in patients on hemodialysis (HD). *J Am Soc Nephrol.* 2012,23.
22. Aleeza J. Roth, Jacob Hess, Mirjan M. Van timmeren, PhD, Elisabeth Berg, Caroline J. Poulton, Madelyn Burkart, Susan L. Hogan, PhD, Yichun Hu, Patrick H. Nachman, MD, FASN, Coen A. Stegeman, MD, Peter Heeringa, PhD, J. Charles Jennette, MD, Gloria A. Preston, PhD, Ronald J. Falk [FR-OR135]. ANCA epitope specificity determines pathogenicity. *J Am Soc Nephrol.* 2012, 23.
23. Taewoo Lee, MD, Andrea K. Biddle, PhD, Sean Barbour, MD, Sophia Lionaki, MD, Yichun Hu, Vimal K. Derebail, MD, Michelle A. Hladunewich, MD, FASN, Caroline J. Poulton, Shannon L. Mahoney, Susan L. Hogan, PhD, Shannon L. Mahoney, Ronald J. Falk, MD, FASN, Daniel C. Cattran, MD, Heather N. Reich, MD, PhD, Patrick H. Nachman [FR-OR127] Prophylactic anticoagulation in membranous nephropathy: a decision analysis. *J Am Soc Nephrol.* 2012,23.
24. Donna O. Bunch, PhD, JulieAnne G. McGregor, MD, Lydia Aybar, Kerry R. Colby, MD, Yichun Hu, Susan L. Hogan, PhD, Caroline J. Poulton, Elisabeth Berg, John Schmitz, Ronald J. Falk, MD, FASN, Patrick H. Nachman, [FR-OR137] Reduced CD5+ B cells in active anti-neutrophil cytoplasmic autoantibody vasculitis and relapse after rituximab. *J Am Soc Nephrol.* 2012,23.
25. Duvuru Geetha, MD, FASN, Caroline J. Poulton, Yichun Hu, Philip Seo, MD, JulieAnne G. McGregor, MD, Patrick H. Nachman [SA-PO316]. Clinical characteristics and outcome of pauci-immune glomerulonephritis in African Americans. *J Am Soc Nephrol.* 2012,23.
26. Taewoo Lee, MD, Vimal K. Derebail, MD, Caroline J. Poulton, Sophia Lionaki, MD, JulieAnne G. McGregor, MD, Susan L. Hogan, PhD, J. Charles Jennette, MD, Ronald J. Falk, MD, FASN, Patrick H. Nachman [SA-PO318]. Prognosis of ANCA-associated glomerulonephritis (ANCA-GN) requiring dialysis at presentation. *J Am Soc Nephrol.* 2012,23.
27. Roberto Negrete, MD, JulieAnne G. McGregor, MD, Caroline J. Poulton, Yichun Hu, Patrick H. Nachman, MD, FASN, Ronald J. Falk, MD, FASN, Susan L. Hogan [SA-PO328]. Infection and mortality in anti-neutrophil cytoplasmic antibody-associated vasculitis. *J Am Soc Nephrol.* 2012,23.
28. Louis-Philippe Laurin, MD, JulieAnne G. McGregor, MD, Vimal K. Derebail, MD, Susan L. Hogan, PhD, Caroline J. Poulton, Adil MH Gasim, MD, J. Charles Jennette, MD, Ronald J. Falk, MD, FASN, Patrick H. Nachman [SA-PO380]. Role of immunosuppressive therapy in renal survival in collapsing focal segmental glomerulosclerosis (FSGS) *J Am Soc Nephrol.* 2012,23.
29. Freedman BI, Hicks PJ, Langefeld CD, Lingyi L, Bleyer AJ, Divers J, Nachman PH, Derebail VK, Bowden DW. Sickle cell trait is not associated with ESRD susceptibility in African Americans. *J Am Soc Nephrol.* 2011,22.
30. Irazabal MV, Eirin A, Lieske JC, Beck LH, Dillon JJ, Nachman PH, Sethi S, Erickson SB, Cattran DC, Fervenza FC. Urinary biomarkers as predictors of response to rituximab in patients with membranous nephropathy. *J Am Soc Nephrol.* 2011,22.
31. Lionaki S, Barbour S, Hu Y, Hogan SL, Jennette CE, Falk RJ, Cattran DC, Nachman PH, Reich HN. The occurrence of cancer in patients with membranous nephropathy. *J Am Soc Nephrol.* 2011,22.

32. Mahoney SL, Derebail VK, Biddle A, Hu Y, Hladunewich MA, Falk RJ, Cattran DC, Reich HN, Nachman PH. Factors influencing treatment choice in idiopathic membranous nephropathy (IMN). *J Am Soc Nephrol.* 2011;22.
33. McGregor JAG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH. Corticosteroid therapy beyond 6 months does not decrease relapse in ANCA disease. *J Am Soc Nephrol.* 2010;21.
34. Lionaki S, Derebail V, Hogan SL, Hladunewich M, Barbour S, Hu Y, Jennette CE, Jennette JC, Falk RJ, Cattran DC, Nachman PH, Reich HN. Hypoalbuminemia is a risk factor of venous thromboembolism in membranous nephropathy (MN). *J Am Soc Nephrol.* 2010;21.
35. Geetha D, Eirin A, True KA, Irazabal-Mira MV, Specks U, Seo P, Nachman PH, Fervenza FC. A multicenter Experience of Kidney Transplantation in ANCA-associated vasculitis (AAV) in the era of modern immunosuppression. *J Am Soc Nephrol.* 2010;21.
36. Fervenza FC, Abraham R, Erickson SB, Irazabal-Mira MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LTJ, Cattran DC. Efficacy, durability and immunological analyses following rituximab therapy in idiopathic membranous nephropathy: a 2-year study. *J Am Soc Nephrol.* 2010;21.
37. Lionaki S, Hogan SL, Hu Y, Jennette CE, Nachman PH, Jennette JC, Falk RJ. Current Classification Systems for ANCA-SVV: Differences in ANCA specificity and predictive value for outcomes. *J Am Soc Nephrol.* 2009;20.
38. Fervenza FC, Erickson SB, Nachman PH, Dillon JJ, Leung N, Hogan MC, Hickson LT, Qazi Q, Bergstralh EJ, Irazabal MV, Erin A, Cattran DC. Rituximab (RTX) in the treatment of idiopathic membranous nephropathy (IMN). *J Am Soc Nephrol.* 2009;20.
39. Fervenza FC, Erickson SB, Nachman PH, Dillon JJ, Leung N, Hogan MC, Hickson LT, Anand B, Visich J, Irazabal MV, Eirin A, Cattran DC. Pharmacokinetics (PK) of rituximab in idiopathic membranous nephropathy (IMN). *J Am Soc Nephrol.* 2009;20.
40. Irazabal MV, Eirin A, Lieske J, Borland TM, Erickson SB, Dillon JJ, Nachman PH, Cattran DC, Fervenza FC. Fractional excretion of high and low molecular weight proteins correlates with response to rituximab (RTX) therapy in patients with idiopathic membranous nephropathy (MN): A prospective study. *J Am Soc Nephrol.* 2009;20.
41. Derebail VK, Nachman PH, Key N, Falk RJ, Kshirsagar AV. High prevalence of sickle cell trait in African-Americans with end-stage renal disease. *J Am Soc Nephrol.* 2009;20.
42. Eirin A, Irazabal MV, Abraham RS, Erickson SB, Nachman PH, Lieske JC, Leung N, Dillon JJ, Cattran DC, Fervenza FC. Quantification of B cell and T cell subsets do not predict response to rituximab therapy in patients with idiopathic membranous nephropathy: a prospective study. *J Am Soc Nephrol.* 2009;20.
43. Lionaki S, Hogan S, Hu Y, Jennette CE, Nachman PH, Jennette JC, Falk RJ. Antigen specificity of ANCA correlates with both clinical expression and prognosis in ANCA small vessel vasculitis (SVV). *J Am Soc Nephrol.* 2009;20.
44. Valdes RA, Key NS, Schmitz JL, Nachman P, Bunch D, Burkart ME, Jennette JC, Falk RJ, Detwiler R. Class II HLA expression in HUVEC derived microparticles during apoptosis and cellular activation. *APMIS* 2009;117:131.
45. Lionaki S, Hogan SL, Hu Y, Jennette CE, Nachman PH, Jennette JC, Falk RJ. Current classification systems for ANCA-SVV: differences in ANCA specificity and predictive value for outcomes. *APMIS* 2009;117:146.
46. Lionaki S, Hogan SL, Hu Y, Jennette CE, Senior B, Nachman PH, Jennette JC, Falk RJ. Specificity of ANCA portrays both clinical expression and prognosis in ANCA vasculitis. *APMIS* 2009;117:152.
47. Fervenza FC, Erickson SB, Dillon JJ, Nachman P, Hogan MC, Haugen EN, Leung N, Wochos DN, Cattran DC. Angiotensin II (Ang II) blockade is ineffective in reducing proteinuria in patients with severe membranous nephropathy (MN). *J Am Soc Nephrol.* 2008;19:559A.

48. S. L. Hogan, S. Lionaki, C. E. Jennette, Y. Hu, J. C. Jennette, R. J. Falk, P. H. Nachman. The association of perionasal and family history of autoimmune disease in development of membranous nephropathy (MN): a case-control study. *J Am Soc Nephrol.* 2008;19:970A.
49. D. O. Bunch, N. B. Khandoobhai, M. A. Amamoo, S. L. Hogan, J. B. Hamra, J. K. Piscitello, R. J. Falk, P. H. Nachman. Rituximab normalizes some B cell phenotypes. *J Am Soc Nephrol.* 2008;19:661A.
50. S. Lionaki, S. L. Hogan, C. E. Jennette, Y. Hu, J. B. Hamra, J. C. Jennette, R. J. Falk, P. H. Nachman. Clinical course of ANCA small vessel vasculitis (SVV) on chronic dialysis. *J Am Soc Nephrol.* 2008;19:783A.
51. S. L. Hogan, D. S. Gipson, M. Ferris, C. E. Jennette, Y. Hu, P. H. Nachman, J. C. Jennette, R. J. Falk. The life course of body weight and development of focal segmental glomerulosclerosis (FSGS): a case-control study. *J Am Soc Nephrol.* 2008;19:328A.
52. Susan L. Hogan, Sofia Lionaki, Caroline E. Jennette, Yichun Hu, J. Charles Jennette, Ronald J. Falk, Patrick H. Nachman, Abhijit Kshirsagar. The role of infection in the development of membranous nephropathy (MN): A case-control study. *J Am Soc Nephrol.* 2008;19:328A.
53. S. L. Hogan, S. Vupputuri, S. Lionaki, C. E. Jennette, Y. Hu, J. C. Jennette, R. J. Falk, P. H. Nachman. Association of heavy metals with the development of membranous nephropathy (MN): a case-control study. *J Am Soc Nephrol.* 2008;19:329A.
54. S. Lionaki, S. L. Hogan, J. C. Jennette, C. E. Jennette, K. Hendrickson, Y. Hu, R. J. Falk, P. H. Nachman. Epidemiology of malignancy in patients with membranous nephropathy (MN). *J Am Soc Nephrol.* 2008;19:329A.
55. Bunch DO, Khandoobhai NB, Amamoo A, Chin H, Hogan SL, Hamra JB, Falk RJ, Nachman PH. Alterations in B cell phenotypes in patients with ANCA vasculitis: correlation with disease activity. *J Am Soc Nephrol.* 2007;18:192A.
56. Lionaki S, Chin H, Hogan SL, Senior BA, Jennette CE, Cooper JD, Nachman PH, Jennette JC, Falk RJ. Comparison of ear, nose and throat (ENT) manifestations in ANCA-small vessel vasculitis (ANCA-SVV): Wegener's granulomatosis (WG) versus microscopic polyangiitis (MPA). *J Am Soc Nephrol.* 2007;18:784A.
57. R A Valdes, N S Key, J L Schmitz, G Kemeny, P Nachman, D Alcorta, K True, D Bunch, M E Burkart, J C Jennette, R J Falk and R Detwiler. A novel approach to measuring microparticles (MPs) using HLA Class I (HLA-1). *J Am Soc Nephrol.* 2007;18:226A.
58. Xiao H, Zhang B, Schreiber A, WenSui, Erdbrugger U, Bunch DO, Hellmark T, Nachman PH, Falk RJ, Jennette JC. Recombinant mouse myeloperoxidase (MPO) induces necrotizing and crescentic glomerulonephritis in mice. *J Am Soc Nephrol.* 2007;18:190A.
59. Cooper JD, Hogan SL, Chin H, Falk RJ, Nachman PH. Mycophenolate mofetil (MMF) + cyclosporine-A (CyA) therapy for active ANCA vasculitis. *J Am Soc Nephrol.* 2006;17:574A.
60. Gibson KL, Chin H, Nester C, Massengill S, Hogan SL, Nachman P, Wong C, Falk RJ, Thomas DB, Gipson DB. Treatment and survival outcomes of ANCA vasculitis in children versus adults. *J Am Soc Nephrol.* 2006;17:732A.
61. Chin H, Pagnoux C, Hogan SL, Guillevin L, Falk RJ, Nachman PH. Predictors of relapse in ANCA vasculitis: comparison of 2 independent cohorts. *J Am Soc Nephrol.* 2006;17:802A.
62. Bunch DO, Khandoobhai NB, Clarke SH, Falk RJ, Nachman PH. Regulators of B cell receptor signaling are altered in patients with ANCA vasculitis. *J Am Soc Nephrol.* 2006;17:353A.
63. Bunch DO, Khandoobhai N, Chin H, Hogan SL, Clarke SH, Falk RJ, Nachman PH. B cell subpopulations are altered in patients with active ANCA vasculitis. *J Am Soc Nephrol.* 2005;16:778A.
64. Hogan SL, Joy MS, Chin H, Jennette JC, Falk RJ, Nachman PH. Strong association of thyroid disease and its treatment with ANCA-SVV. *J Am Soc Nephrol.* 2005;16:555A.
65. Jennette CE, Chin H, Falk RJ, Nachman PH, Hogan SL. Delay of diagnosis in patients with ANCA small vessel vasculitis. *J Am Soc Nephrol.* 2005;16:555A.

66. Radhakrishnan J, Weiss S, Nachman P, Adler S, Appel G. Rituximab (RMB) in glomerular disease (GD). *J Am Soc Nephrol.* 2005;16:528A.
67. Erdbruegger U, Hellmark T, Alcorta DA, Bunch DO, Nachman PH. Most myeloperoxidase (MPO)-ANCA show stable binding to a restricted number of epitopes. *J Am Soc Nephrol.* 2004;15:680A.
68. Bunch DO, Silver J, Nachman PH. Anti-MPO B cells of anti-MPO light chain transgenic mice are regulated by deletion and diversion to marginal zone B1 B cells. *J Am Soc Nephrol.* 2004;15:680A.
69. Appel G, Nachman P, Hogan S, Radhakrishnan J, Old C, Hebert L, Fervenza F, Kumor K, Petro B, Lan L, Hardman J. Eculizumab (C5 complement inhibitor) in the treatment of idiopathic membranous nephropathy (IMN): preliminary baseline and pharmacokinetic (PK)/pharmacodynamic (PD) data. *J Am Soc Nephrol.* 2002;13:668A.
70. Erdbruegger U, Hellmark T, Majure MCM, Bunch DO, Nachman PH. Comparative binding of anti-myeloperoxidase (MPO) antibodies to human and mouse MPO. *J Am Soc Nephrol.* 2002;13:174A.
71. Patry Y, Nachman PH, Audrain MAP, Muller J-Y, Falk RJ, Esnault VLM. Difference in antigenic determinant profiles between human and rat myeloperoxidase. *J Am Soc Nephrol.* 2001;12:638A.
72. Hellmark T, Majure MC, Jethwa HS, Clarke SH, Falk RJ, Nachman PH. Variable region gene use in human anti-myeloperoxidase antibodies. *J Am Soc Nephrol.* 2001;12:632A.
73. Itoh-Lindstrom Y, Taylor TV, Clarke SH, Jennette JC, Falk RJ, Nachman PH. Generation of anti-MPO B cells in V ~~luc~~ transgenic mice. *J Am Soc Nephrol.* 2000;11:476A.
74. Taylor TV, Itoh-Lindstrom Y, Clarke SH, Jennette JC, Falk RJ, Nachman PH. Anti-Myeloperoxidase (MPO)-derived light chain confers antibody specificity to MPO. *J Am Soc Nephrol.* 2000;11:483A.
75. Nachman PH, Joy MS, Hogan SL, Jennette JC, Falk RJ. Preliminary results of a pilot study on the use of mycophenolate mofetil (MMF) in relapsing ANCA small vessel vasculitis (ANCA-SVV). *J Am Soc Nephrol.* 2000;11:158A.
76. ten Holder S, Hogan SL, Nachman PH, Jennette JC, Falk RJ. Response to corticosteroids (CS) and ACE inhibitors/ACE receptor antagonists (ACEi/ARB) in a contemporary cohort of patients with focal segmental glomerulosclerosis (FSGS). *J Am Soc Nephrol.* 2000;11:99A.
77. Hogan SL, ten Holder S, Nachman PH, Wilkman AS, Jennette JC, Falk RJ. Predictors of outcome in a contemporary cohort of patients with focal segmental glomerulosclerosis (FSGS). *J Am Soc Nephrol.* 2000;11:87A.
78. Itoh-Lindstrom Y, Taylor TV, Clarke SH, Jennette JC, Falk RJ, Nachman PH. Vk1C light-chain transgenic mice—a mouse model for anti-MPO B cell regulation. *Clin Exp Immunol.* 2000,120(Suppl 1):45.
79. Nachman PH, Joy MS, Hogan SL, Jennette JC, Falk RJ. Mycophenolate Mofetil (MMF): Preliminary results of a feasibility trial in relapsing ANCA small vessel vasculitis. *Clin Exp Immunol.* 2000, 120(Suppl 1):72.
80. Hogan SL, Nachman PH, Jennette JC, and Falk RJ. The role of ANCA pattern and diagnosis in clinical presentation and outcomes in ANCA-associated small vessel vasculitis (ANCA-SVV). *J Am Soc Nephrol.* 1999;10:104A.
81. Satterly KK, Hogan SL, Nachman PH, Dooley MA, Jennette JC, Falk RJ. ANCA-associated diseases with renal involvement but not lupus nephritis are associated with silica exposure. *Clin Exp Immunol.* 1998, 112(Suppl 1):25.
82. Kopp JB, Vlahov D, Macalino G, Briggs WA, Korbet SM, Berns JS, Kimmel PL, Welch TR, Smith MC, Schelling JR, Simon E, Nachman PH, Hutchison F, Rao TKS, Ripley E, Wachter L, Nelson G, Winkler C. Candidate gene analysis in focal segmental glomerulosclerosis among African-Americans. *J Am Soc Nephrol.* 1998;9:390A.
83. Joy MS, Cefalu WT, Hogan SL, Kirby R and Nachman PH. Assessment of measures of long-term glycemic control in diabetic patients with ESRD. *J Am Soc Nephrol.* 1998;9:117A.
84. Nachman PH, Hogan SL, Satterly KK, Jennette JC, Falk RJ. Recurrent ANCA-small vessel vasculitis (SVV) and glomerulonephritis (GN) after transplantation: a pooled analysis. *J Am Soc Nephrol.* 1997;8:696A.

85. Nachman PH, Dooley MA, Hogan SL, Aiello JR, Jennette JC, Falk RJ for the Glomerular Disease Collaborative Network (GDCN). Mycophenolate mofetil therapy in patients with cyclophosphamide (CyP) resistant or relapsing diffuse proliferative lupus nephritis (SLE-DPGN). *J Am Soc Nephrol.* 1997;8:94A.
86. Nachman PH, Hogan SL, Dooley MA, Satterly KK, Jennette JC, Falk RJ for the Glomerular Disease Collaborative Network (GDCN). Remission and relapse in ANCA small vessel vasculitis (SVV) by ANCA antigen specificity and by disease category. *J Am Soc Nephrol.* 1997;8:94A.
87. Hogan SL, Nachman PH, Dooley MA, Satterly KK, Jennette JC, Falk RJ for the Glomerular Disease Collaborative Network (GDCN). ANCA antigen specificity in 192 patients with glomerulonephritis (GN), microscopic polyangiitis (MPA), or Wegener's granulomatosis (WG). *J Am Soc Nephrol.* *J Am Soc Nephrol* 1997;8:87A.
88. Morris CR, Hogan SL, Nachman PH: Meta-analysis of randomized trials using mycophenolate mofetil (MMF) in renal transplantation. *J Am Soc Nephrol.* 1997;8:695A.
89. Jethwa HS, Clarke S, Taylor JG, Jennette JC, Falk RJ, Nachman PH. Variable region gene selection in murine anti-myeloperoxidase (MPO) autoantibodies. *J Am Soc Nephrol.* 1997;8:457A.
90. Nachman PH, Hogan SL, Dooley MA, Satterly KK, Jennette JC, Falk RJ for the Glomerular Disease Collaborative Network (GDCN). Remission, relapse and side effects in patients with ANCA-small vessel vasculitis (SVV) treated with intravenous (IV) versus oral cyclophosphamide (CyP). *J Am Soc Nephrol.* 1997;8:94A.
91. Nachman PH, Clarke SH, Kinjoh K, Taylor J, Jennette JC, Falk RJ: Cross-reactivity of murine monoclonal auto-antibodies (Mab) to DNA and myeloperoxidase (MPO). *J Am Soc Nephrol.* 1995;3,845.
92. Kinjoh K, Good RA, Taylor J, Nachman PH, Falk RJ, Jennette JC: Hybribomas from SCG/Kj mice produce P-ANCA with specificity for myeloperoxidase (MPO) and induce proteinuria in nude mice. *Clin Exp Immunol.* 1995;101,37.
93. Nachman PH, Royal MO, Kinjoh K, Reisner HM, Jennette JC, Falk RJ: Murine monoclonal anti-MPO autoantibody reacts to an epitope commonly recognized by human ANCA. *Clin Exp Immunol.* 1995;101,38.
94. Nachman PH, Hogan SL, Jennette JC, Falk RJ: Treatment response in ANCA-associated microscopic polyangiitis (MPA) and necrotizing and crescentic glomerulonephritis. *Clin Exp Immunol.* 1995;101,44.
95. Nachman PH, Reisner HM, Jennette JC, Falk RJ: A study of shared idiotypy among patients with myeloperoxidase-ANCA (MPO-ANCA) associated disease. *J Am Soc Nephrol.* 1994;5,839.
96. Nachman PH, Hogan SL, Jennette JC, Falk RJ: A study of relapse in patients with anti-neutrophil cytoplasmic autoantibody ANCA) associated vasculitis. *J Am Soc Nephrol.* 1994;5,838.
97. Nachman PH, Reisner HM, Jennette JC, Falk RJ: The clonality of myeloperoxidase (MPO)-ANCA by isoelectro-focusing. *J Am Soc Nephrol.* 1993;4,622.
98. Nachman PH, Terrell RS, Jennette JC, Falk RJ: Naturally occurring anti-myeloperoxidase (MPO) antibodies. *J Am Soc Nephrol.* 1993;4,622.

ONLINE WEB-BASED TOOL

Decision Aid for Prophylactic Anticoagulation in Patients with Membranous Nephropathy: <http://www.gntools.com>

American Society of Nephrology Post Graduate Education

Post-Graduate Education Committee

Chair: 9/2013-present. As chair of the PGE committee, I am responsible for the development, organization and implementation of clinical continuing education programs at the yearly conference of the American Society of Nephrology (ASN Kidney Week) which draws about 13000 attendees from around the world. This includes 40 Clinical Practice Sessions (2 hours each), 13 In-Depth Nephrology Courses (1 or 2 day courses which attract about 2000 attendees), and 13-15 Educational Sessions (1 hour sessions which attract 300-500 attendees each).

Chair-elect: 9/2012- 9/2013

Member: 2007- 2012. Contributed each year to the organization of Clinical Nephrology Conferences and Educational Symposia.

Glomerulonephritis Update; Diagnosis and Therapy.

Course Co-Chair: A two-day course entirely focused on the pathogenesis, pathology and treatment of glomerular diseases. Attended by 450-500 nephrologists from the US and the world. This is consistently the largest in-depth course offered by the American Society of Nephrology

American Society of Nephrology Renal Week 2013:

Co-Chair Post Graduate Education Program. Glomerulonephritis Update: Diagnosis and Therapy.

American Society of Nephrology Renal Week 2012:

Co-Chair Post Graduate Education Program. Glomerulonephritis Update: Diagnosis and Therapy.

American Society of Nephrology Renal Week 2011:

Co-Chair Post Graduate Education Program. Glomerulonephritis Update: Diagnosis and Therapy

American Society of Nephrology Renal Week 2010:

Co-Chair Post Graduate Education Program. Glomerulonephritis Update: Diagnosis and Therapy.

American Society of Nephrology Renal Week 2009:

Co-Chair Post Graduate Education Program. Glomerulonephritis Update: Diagnosis and Therapy.

American Society of Nephrology Renal Week 2008:

Co-Chair Post Graduate Education Program. Glomerulonephritis Update: Diagnosis and Therapy.

American Society of Nephrology Renal Week 2007:

Co-Chair Post Graduate Education Program. Glomerulonephritis Update: Diagnosis and Therapy. 10/31-11/1/07

Nephrology Self Assessment Program. NephSAP

Associate Editor: 2007- 2014

NephSAP Contributions:

Nachman PH and Glassock R. Co-Editor. Glomerular, Vascular, and Interstitial Diseases of the Kidney. Nephrology Self-Assessment Program.(NephSAP) .J Am Soc Nephrol. NephSAP, 2014 online publication.

Clark W, Derebail VK and Nachman PH. Co editor, Vaso-occlusive Diseases of the Kidney Nephrology Self Assessment Program (NephSAP). January 2014 Online publication

Nachman PH and Glassock R. Co-Editor. Glomerular, Vascular, and Interstitial Diseases of the Kidney. Nephrology Self Assessment Program.(NephSAP). 2012; 11:140-217

Nephrology Self Assessment Program.(NephSAP). 2010; 9:123-200

Nachman PH and Glassock R. Co-Editor. Glomerular, Vascular, and Interstitial Diseases of the Kidney. Nephrology Self Assessment Program.(NephSAP). 2008;7,131-207

Glomerular Disease Advisory Committee

Member: 2008-2014

ONGOING GRANTS AND PROJECTS

Ongoing Research Support

P01 DK058335, NIH/NIDDK 2000-07-01 to 2020-06-30

Falk, Ronald J. (PI)

ANCA Glomerulonephritis: From Molecules to Man

Co-Project leader for Project IV (clinical) This program project consists of 4 projects and two cores focusing on anti-neutrophil cytoplasmic autoantibody (ANCA) necrotizing and crescentic glomerulonephritis and small vessel vasculitis (SVV). The scope of the investigation and the diversity of the investigators allow for an integrated evaluation of myeloperoxidase (MPO) and proteinase 3 (PR3) autoimmune response.

Role: Co-Investigator

UM1 DK100867, NIH/NIDDK 2014-07-01 to 2019-07-01

Falk, Ronald J. (PI)

GDCN Clinical Center-Advancing Clinical Research in Primary Glomerular Diseases (CureGN)

Multicenter Longitudinal Cohort Study of Primary Glomerular Diseases: Membranous Nephropathy, Focal Segmental Glomerulosclerosis, Minimal Change Disease and IgA Nephropathy.

Role: Co-Investigator

ORD, ORD/NIDDK/UMich/NephCure 2014-07-01 to 2019-06-30

Kretzler, Matthias (PI)

NEPhrotic Syndrome sTUDy NEtwork (NEPTUNE): Administrative part

To establish a collaborative, integrated, investigational infrastructure to conduct clinical and translational research in FSGS, Minimal Change Disease, and Membranous Nephropathy to perform a longitudinal observational cohort study of patients who present with biopsy-proven FSGS, MCD or MN; to administer pilot and ancillary projects program that coordinates studies that employ the unique resources, clinical data, or specimens assembled by NEPTUNE.

Role: Co-Investigator

1U54DK083912-01 , Office of Rare Diseases/NIDDK/NIH 2014-09-01 to 2019-06-30

Matthias Kretzler (PI)

NEPhrotic Syndrome sTUDy NEtwork (NEPTUNE): Clinical part

UNC PI. The UNC Kidney Center is one site for this multi-center, multidisciplinary research and education platform that brings together clinical and translational scientists and two lay research and patient education foundations to better study focal segmental glomerulosclerosis, membranous nephropathy and minimal change disease.

Role: Co-Investigator

DK007750, NIH/NIDDK 1999-01-01 to 2018-09-01

Falk, Ronald J (PI)

Renal Epidemiology Training Grant

NIH/Institutional National Research Service Award The primary purpose of the training grant is to prepare trainees to design and carry out independent research in the diverse field of renal disease. This training program will emphasize three components: course work, research projects and specialized training.

Role: KP

(b) (4)

ISRCTN07757494, European Vasculitis Study Group (EUVAS) and the Vasculitis Clinical Research Consortium (VCRC) 2010-07-01 to 2016-07-01

Peter Merkel (PI)

Plasma exchange and glucocorticoid dosing in the treatment of ANCA-associated vasculitis: an international randomized controlled trial. UNC Site PI. This is a multicenter international randomized controlled trial to

evaluate the role of plasma exchange and glucocorticoid dosing in the induction treatment of patients with severe ANCA associated vasculitis. Role: UNC PI

Past Research Support

2P01DK058335-06 (Falk, PI)

9/1/2000-8/30/2015

2.5 calendar months

NIH/NIDDK

ANCA Glomerulonephritis: From Molecules to Man

This program project consists of 4 projects and two cores focusing on anti-neutrophil cytoplasmic autoantibody (ANCA) necrotizing and crescentic glomerulonephritis and small vessel vasculitis (SVV).

The scope of the investigation and the diversity of the investigators allow for an integrated evaluation of myeloperoxidase (MPO) and proteinase 3 (PR3) autoimmune response.

Project 4: Translation of knowledge on the pathogenesis of ANCA disease into novel therapy

Goals: to test the impact of our advances in understanding the immunopathogenesis of ANCA on the course and treatment of the disease in humans through novel approaches to therapy.

Role: Project leader (20% effort)

Budget: \$148,226

NIH Core A: Clinical Core

Goals: to collect, process and store biologic samples from patients at various stages of their disease as well as from controls, monitor and manage information on the long-term outcomes in patients with ANCA disease using standard definitions in the field, and, manage, integrate and process the medical and biologic information from components of all projects, from development of data collection forms to management of the database, to statistical analyses and interpretation of results for presentations and publications.

Role: Co-investigator

Budget: \$151,945 (5% effort)

Development of a Decision Support Tool for Nephrotic Syndrome Management

Sponsor: Patient-centered Outcomes Research Institute (PCORI)

The UNC Kidney Center is one site out of 3 performance sites involved in this project.

Role: UNC site Principal Investigator

Period: 10/23/2012 – 12/31/2013

NEPhrotic Syndrome STUdy NETwork (NEPTUNE): Clinical part

Goal: determine rates and predictors of clinical remission of focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and membranous nephropathy (MN),

Communicating Principal Investigator: Matthias Kretzler, M.D. University of Michigan Medical School

Role: Site Principal Investigator (5% effort)

Period: 07/01/2010 – 06/30/2020

Effort: 5%

NEPhrotic Syndrome STUdy NETwork (NEPTUNE): Administrative contract

Goal: to establish a collaborative, integrated, and cost-effective investigational infrastructure to conduct clinical and translational research in Focal and Segmental Glomerulosclerosis, Minimal Change Disease, and Membranous Nephropathy to perform a longitudinal observational cohort study of patients who present with biopsy-proven FSGS, MCD or MN; to administer a pilot and ancillary projects program that selects, supports, and coordinates studies that employ the unique resources, clinical data, or specimens assembled by NEPTUNE; to implement a training program designed for advanced post-doctoral and junior faculty trainees, or established investigators interested in redirecting their investigative focus, who are preparing to become independent investigators in clinical and translational research in human glomerular disease;

Communicating Principal Investigator: Matthias Kretzler, M.D. University of Michigan Medical School

Role: Project leader (10% effort)

Period: 07/01/2010 – 06/30/2020

Effort: 10%

DK007750 (Falk, PI)

03/01/99-02/28/14

1.20 calendar

Renal Epidemiology Training Program

\$258,703

NIH/Institutional National Research Service Award

The primary purpose of the training grant is to prepare trainees to design and carry out independent research in the diverse field of renal disease. This training program will emphasize three components: course work, research projects and specialized training.

Role: Mentor

Plasma exchange (PLEX) and glucocorticoids for treatment of ANCA-associated vasculitis (PEXIVAS):

Communicating Principal Investigator: Peter Merkel, MD, Boston University

Goals: To determine the efficacy of PLEX in addition to immunosuppressive therapy and GC in reducing death and end-stage renal disease (ESRD) and to determine the non-inferiority of a reduced-dose GC regimen in reducing death and ESRD

Role: Site Principal Investigator

Period: 04/01/2010 – present (projected completion 2017)

Budget: \$ (b) (4)

Per patient support

North American Sponsor: University of Pennsylvania (US and Canada) : RITAZAREM : An international, open label, randomised controlled trial comparing rituximab with azathioprine as maintenance therapy in relapsing ANCA-associated vasculitis

Aim: To demonstrate the superiority of rituximab against azathioprine in the prevention of disease flare in AAV patients with relapsing disease

Role: UNC Site Principal Investigator.

Period: Sept 2013- projected completion 5 years

(b) (4)



PROFESSIONAL SERVICE

To discipline

- ◆ American Society of Nephrology: Postgraduate Education Committee. August 2007- present, Committee Chair September 2013-present
- ◆ American Society of Nephrology: Glomerular Disease Advisory Committee 2008-2014
- ◆ FSGS Internal Medicine Committee NIH FSGS trial 2007- 2009
- ◆ NIAID: Special Emphasis Panel reviewing applications in response to RFA AI-98-001 “Human Immunology Centers of Excellence”. Member, February-March 1998

Within UNC

- ◆ Faculty at Large Committee: August 2013- present
- ◆ Office of Human Research Ethics: Biomedical Institutional Review Board: March 2002- 2009
- ◆ General Clinical Research Center Scientific Advisory Committee: 1997-2012

Manuscript reviews for major nephrology and rheumatology journals, 1996-present

American Journal of Kidney Disease
Arthritis and Rheumatology
Clinical Journal of the American Society of Nephrology
Journal of the American Society of Nephrology
Kidney International
JAMA